Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price […]
Related Keywords
United States , Switzerland , Ireland , Belgium , Japan , Michaelj Labarre , , Goldman Sachs Group , Townsquare Capital , Morgan Stanley , Nasdaq , Halozyme Therapeutics Inc , Securities Exchange Commission , Capital Partners , Virtu Financial , Halozyme Therapeutics , Get Free Report , Exchange Commission , Ivy Capital Management , Investment Counsel , Get Free , Halozyme Therapeutics Daily , Nasdaq Halo , Halo , Medical , 40637h10 , Ratings , Consensus ,
vimarsana.com © 2020. All Rights Reserved.